Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study

Table 3 Summary of R0 resection rates

Reason for surgery	Residual disease	n (%)1
Curative
	No (radical surgery)	26 (55.8)
	Yes	7 (13.5)
	Unknown	2 (3.9)
	Not applicable	4 (7.7)
Palliative
	No (radical surgery)	2 (3.9)
	Yes	4 (7.7)
	Unknown	2 (3.9)
	Not applicable	1 (1.9)
Biopsy
	Yes	1 (1.9)
	Not applicable	1 (1.9)
Unknown
	Unknown	1 (1.9)
	Not applicable	2 (3.9)
Other
	Yes	1 (1.9)
	Not applicable	2 (3.9)

¹Values reported as number of patients and, in parentheses, percentage on total number of patients who underwent R0 resection. Patients are counted only once in each row. Each patient could have more than one surgery during the study period.